1. Home
  2. TOVX vs LIXT Comparison

TOVX vs LIXT Comparison

Compare TOVX & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TOVX
  • LIXT
  • Stock Information
  • Founded
  • TOVX 2001
  • LIXT 2005
  • Country
  • TOVX United States
  • LIXT United States
  • Employees
  • TOVX N/A
  • LIXT N/A
  • Industry
  • TOVX Biotechnology: Pharmaceutical Preparations
  • LIXT Biotechnology: Pharmaceutical Preparations
  • Sector
  • TOVX Health Care
  • LIXT Health Care
  • Exchange
  • TOVX Nasdaq
  • LIXT Nasdaq
  • Market Cap
  • TOVX 4.7M
  • LIXT 4.1M
  • IPO Year
  • TOVX 2006
  • LIXT N/A
  • Fundamental
  • Price
  • TOVX $1.18
  • LIXT $1.19
  • Analyst Decision
  • TOVX Strong Buy
  • LIXT
  • Analyst Count
  • TOVX 1
  • LIXT 0
  • Target Price
  • TOVX $6.00
  • LIXT N/A
  • AVG Volume (30 Days)
  • TOVX 23.5K
  • LIXT 31.5K
  • Earning Date
  • TOVX 05-06-2025
  • LIXT 03-24-2025
  • Dividend Yield
  • TOVX N/A
  • LIXT N/A
  • EPS Growth
  • TOVX N/A
  • LIXT N/A
  • EPS
  • TOVX N/A
  • LIXT N/A
  • Revenue
  • TOVX N/A
  • LIXT N/A
  • Revenue This Year
  • TOVX N/A
  • LIXT N/A
  • Revenue Next Year
  • TOVX N/A
  • LIXT N/A
  • P/E Ratio
  • TOVX N/A
  • LIXT N/A
  • Revenue Growth
  • TOVX N/A
  • LIXT N/A
  • 52 Week Low
  • TOVX $1.03
  • LIXT $1.02
  • 52 Week High
  • TOVX $12.25
  • LIXT $3.74
  • Technical
  • Relative Strength Index (RSI)
  • TOVX 44.04
  • LIXT 39.25
  • Support Level
  • TOVX $1.08
  • LIXT $1.17
  • Resistance Level
  • TOVX $1.21
  • LIXT $1.29
  • Average True Range (ATR)
  • TOVX 0.07
  • LIXT 0.09
  • MACD
  • TOVX 0.00
  • LIXT 0.02
  • Stochastic Oscillator
  • TOVX 57.89
  • LIXT 12.50

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: